Brief: Monopar Announces Successful Advancement Of Camsirubicin Early Stage Study Past Fourth Cohort
18/01/2023 13:52
Jan 18 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR ANNOUNCES SUCCESSFUL ADVANCEMENT OF CAMSIRUBICIN
PHASE
1B CLINICAL TRIAL PAST FOURTH COHORT, ESCALATES NEXT TO 650MG/M2
Source text for Eikon: ID:nGNX75Lx7y
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla